Curriculum Vitae

Gregory S. Fitzgerald, PhD · Behavioral Neuroscientist

Albany, NY · greg.s.fitzgerald@gmail.com · linkedin.com/in/gregsfitzgerald · github.com/gregfitzgerald · ORCID 0000-0003-1186-6259

Full CV below, or download a PDF. The two resumes are the same history cut for different roles.

Profile

Behavioral neuroscientist and quantitative researcher with preclinical and analytical experience across academic and industry-adjacent settings. First-author and contributing-author publications in Alzheimer's therapeutics, whole-brain imaging, and applied machine learning. Methodological strengths in systematic evidence synthesis, reproducible statistical pipelines (R, Python), and translational research.

Education

Ph.D., Behavioral Neuroscience 2026
State University of New York at Albany
B.A., Neuroscience -⁠- Magna Cum Laude 2013
Queens College, City University of New York

Minor: Japanese

Research & Professional Experience

Doctoral Research Scientist -⁠- Stellar Lab 2016 -⁠- 2026
State University of New York at Albany
  • Ran an independent preclinical research program testing IGF-2 (a neurotrophic factor) and metabolic interventions in rodent Alzheimer's models; first-author publication in CNS Neuroscience & Therapeutics (2023).
  • Built an automated evidence-synthesis pipeline in R and Python for a systematic cross-species meta-analysis; identified a 2.5x effect-size gap between rodent and human cognitive findings.
  • Executed the full experimental pipeline: intranasal compound administration, cognitive phenotyping (fear, spatial, and working memory), hippocampal cell culture, ICC, ELISA, and Western blot.
Laboratory Technician & Manager -⁠- Osten Lab 2011 -⁠- 2016
Cold Spring Harbor Laboratory
  • Contributing author to a Cell publication (2017): validated transgenic mouse lines with IHC and contributed to serial two-photon tomography for whole-brain, single-cell-resolution mapping of GABAergic neuron distribution.
  • Studied the neurobiology of social behavior in Cntnap2 knockout autism models via stereotaxic viral injections, confocal microscopy, and IHC.
  • Promoted from technician to lab manager: ran the animal colony, genotyping pipeline, procurement, and budgets; coordinated across postdoctoral research teams.
Adjunct Instructor, Statistics 2020 -⁠- 2026
SUNY Albany & Hudson Valley Community College
  • Primary instructor for undergraduate statistics across six years with excellent student evaluations; designed curriculum, assessments, and grading; mentored 16 undergraduate researchers.
Undergraduate Research Assistant -⁠- Bodnar Lab 2009 -⁠- 2011
Queens College, City University of New York
  • Co-authored two peer-reviewed publications on reward-circuitry neuropharmacology; mapped brain activation via c-Fos immunohistochemistry in mesocorticolimbic regions.
Founder -⁠- EE Performance 2021
  • Preclinical-stage biotech concept built around exogenous exerkines as exercise mimetics for Alzheimer's disease; developed the scientific and commercial rationale, competed in the UAlbany Blackstone LaunchPad venture competition, and completed a patent-landscape analysis.
Research Collaborator -⁠- Metascience Observatory 2025 -⁠- present
with D. Elton (NIH/NIST)
  • Building the automated meta-analysis pipeline behind a systematic assessment of research replicability across scientific fields; reproducible one-command analysis pipelines in Python and R.

Peer-Reviewed Publications

  1. Kim Y, Yang GR, Pradhan K, Venkataraju KU, Bota M, Garcia del Molino LC, Fitzgerald G, Ram K, He M, Levine JM, Mitra P, Huang JZ, Wang X-J, Osten P. Brain-wide Maps Reveal Stereotyped Cell-Type-Based Cortical Architecture and Subcortical Sexual Dimorphism. Cell. 2017;171(2):456-469.
  2. Fitzgerald GS, Chuchta TG, McNay EC. Insulin-like growth factor-2 is a promising candidate for the treatment and prevention of Alzheimer's disease. CNS Neuroscience & Therapeutics. 2023. [PDF]
  3. Ralbovsky NM, Fitzgerald GS, McNay EC, Lednev IK. Raman spectroscopy and machine learning for Alzheimer's disease screening. Spectrochimica Acta Part A. 2021.
  4. Kraft TT, Yakubov Y, Huang D, Fitzgerald G, Natanova E, Sclafani A, Bodnar RJ. Dopamine D1 and opioid receptor antagonists differentially reduce the acquisition and expression of fructose-conditioned flavor preferences in BALB/c and SWR mice. Physiology & Behavior. 2015;151:213-220.
  5. Kraft TT, Yakubov Y, Huang D, Fitzgerald G, Acosta V, Natanova E, Touzani K, Sclafani A, Bodnar RJ. Dopamine D1 and opioid receptor antagonism effects on the acquisition and expression of fat-conditioned flavor preferences in BALB/c and SWR inbred mice. Pharmacology Biochemistry and Behavior. 2013;110:127-136.

Preprints & Works in Progress

Public & Popular Writing

Peer Review

Selected Conference Presentations

Honors & Awards

Technical Skills

Computational & Quantitative: R, Python, SQL, SPSS, GraphPad Prism · Meta-Analysis & Systematic Review · Mixed-Effects & Bayesian Modeling · Applied Machine Learning · Reproducible Pipelines & Data Visualization

Laboratory: Stereotaxic Neurosurgery & Viral Vector Delivery · Microdialysis · Rodent Behavioral Testing · IHC/ICC · Confocal & Two-Photon Microscopy · Western Blot · ELISA · Primary Cell Culture · Colony Management & IACUC